Andrea Jackson

Andrea Jackson is a Director at Northpond Ventures on the firm’s convergent technologies team. Andrea is a Board Director at several digital health and patient engagement companies, including Deep Lens, Hawthorne Effect, Octave Bioscience, Outcomes4Me, and SimBioSys. She is also a Board Director at life science software technology companies, including Saama, Scitara Corporation, Syapse, and VieCure; as well as at R&D solutions companies, including Codex DNA (NASDAQ: DNAY), Elephas Bio, Isolation Bio Inc. (formerly General Automation Lab Technologies), Refeyn, and Vizgen. Andrea also served on the board at Current Health (acquired by Best Buy) and NanoView Biosciences (acquired by Unchained Labs). Previously, Andrea was the commercial lead at Farcast Biosciences, an oncology clinical diagnostic company. Prior to Farcast, Andrea held various senior commercial leadership roles in life science startups and large companies such as PerkinElmer (NYSE: PKI) and Millipore. Before her operating roles, Andrea worked in JPMorgan’s Healthcare Investment Banking team and focused on life science tools, diagnostics, and biotechnology companies. Andrea received an MBA from Kellogg School of Management at Northwestern University and a B.A. with honors from Washington University in St. Louis.
Top